The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Abstract
PURPOSE: To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-hour continuous intravenous infusion (CIV). PATIENTS AND METHODS: Forty-seven patients with refractory neoplasms received UCN-01 during this phase I trial. Total, free plasma, and salivary concentrations were determined; the latter were used to address the influence of plasma protein binding on peripheral tissue distribution. The phosphorylation state of the protein kinase C (PKC) substrate alpha-adducin and the abrogation of DNA damage checkpoint also were assessed. RESULTS: The recommended phase II dose of UCN-01 as a 72-hour CIV is 42.5 mg/m 2/d for 3 days. Avid plasma protein binding of UCN-01, as measured during the trial, dictated a change in dose escalation and administration schedules. Therefore, nine patients received drug on the initial 2-week schedule, and 38 received drug on the recommended 4-week schedule. DLTs at 53 mg/m 2/d for 3 days included hyperglycemia with resultant metabolic acidosis, pulmonary dysfunction, nausea, vomiting, and hypotension. Pharmacokinetic determinations at the recommended dose of 42.5 mg/m 2/d for 3 days included mean total plasma concentration of 36.4 μM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h. The mean total salivary concentration was 111 nmol/L of UCN-01. One partial response was observed in a patient with melanoma, and one protracted period ( > 2.5 years) of disease stability was observed in a patient with alk-positive anaplastic large-cell lymphoma. Preliminary evidence suggests UCN-01 modulation of both PKC substrate phosphorylation and the DNA damage-related G 2 checkpoint. CONCLUSION: UCN-01 can be administered safely as an initial 72-hour CIV with subsequent monthly doses administered as 36-hour infusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
(1999) · PubMed · Cited by 1,030
Drug binding to human alpha-1-acid glycoprotein in health and disease.
Kremer, J. M., Wilting, J., & Janssen, L. H. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00015-8 · Cited by 583
Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., & Piwnica-Worms, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5600 · Cited by 544
Self-citationUCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Self-citation(2000) · PubMed · Cited by 314
Carlson, B., Lahusen, T. J., Singh, S., Loaiza‐Perez, A., Worland, P. J., Pestell, R. G., Albanese, C., Sausville, E. A., & Senderowicz, A. M. (1999) · PubMed · Cited by 287
Self-citationPKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro, D., Ruetz, S., Bodis, S. B., Pruschy, M. N., Csermak, K., Man, A., Campochiaro, P. A., Wood, J. M., O'Reilly, T., & Meyer, T. (2000) · PubMed · Cited by 271
Potent and Specific Inhibitors of Protein Kinase C of Microbial Origin
Tamaoki, T., & Nakano, H. (1990) · Nature Biotechnology · doi:10.1038/nbt0890-732 · Cited by 259
(1996) · PubMed · Cited by 221
Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D. J., et al. (1998) · PubMed · Cited by 200
Self-citationAkinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., & Okabe, M. (1991) · PubMed · Cited by 189
Cell cycle-dependent and ATM-independent expression of human Chk1 kinase
Kaneko, Y., Watanabe, N., Morisaki, H., Akita, H., Fujimoto, A., Tominaga, K., Terasawa, M., Tachibana, A., Ikeda, K., & Nakanishi, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202706 · Cited by 169
TAKAHASHI, I., Saitoh, Y., Yoshida, M., Sano, H., Nakano, H., Morimoto, M., & Tamaoki, T. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.571 · Cited by 158
Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Seynaeve, C., Kazanietz, M. G., Blumberg, P. M., Sausville, E. A., & Worland, P. J. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10590-7 · Cited by 158
Self-citationAkiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., & Akinaga, S. (1997) · PubMed · Cited by 152
Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., & Sausville, E. A. (1995) · PubMed · Cited by 136
Self-citationSeynaeve, C., Stetler‐Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., & Worland, P. J. (1993) · PubMed · Cited by 132
Self-citationRole of Human Cds1 (Chk2) Kinase in DNA Damage Checkpoint and Its Regulation by p53
Tominaga, K., Morisaki, H., Kaneko, Y. S., Fujimoto, A., Tanaka, T., Ohtsubo, M., Hirai, M., Okayama, H., Ikeda, K., & Nakanishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31463 · Cited by 116
TAKAHASHI, I., Asano, K., Kawamoto, I., Tamaoki, T., & Nakano, H. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.564 · Cited by 107
1001 Protein Kinases Redux—Towards 2000
Hunter, T. (1994) · Seminars in Cell Biology · doi:10.1006/scel.1994.1044 · Cited by 104
Yu, L., Orlandi, L., Wang, P., Orr, M. S., Senderowicz, A. M., Sausville, E. A., Silvestrini, R., Watanabe, N., Piwnica-Worms, H. M., & O'Connor, P. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33455 · Cited by 103
Self-citationAkinaga, S., Nomura, K., Gomi, K., & Okabe, M. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685899 · Cited by 91
Roberge, M., Berlinck, R. G. S., Xu, L., Anderson, H. J., Lim, L. Y., Curman, D., Stringer, C. M., Friend, S. H., Davies, P., Vincent, I. J., et al. (1998) · PubMed · Cited by 91
Self-citationClinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
Sausville, E. A., Lush, R. D., Headlee, D. J., Smith, A. C., Figg, W. D., Arbuck, S. G., Senderowicz, A. M., Fuse, E., Tanii, H., Kuwabara, T., et al. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051080 · Cited by 88
Self-citationAkinaga, S., Sugiyama, K., & Akiyama, T. (2000) · PubMed · Cited by 78
Shao, R., Cao, C., & Pommier, Y. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31321 · Cited by 65
UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent
Chen, X., Lowe, M., & Keyomarsi, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202948 · Cited by 63
Hecker, M., Preiß, C., & Schini‐Kerth, V. B. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701026 · Cited by 56
Nishimura, H., & Simpson, I. A. (1994) · Biochemical Journal · doi:10.1042/bj3020271 · Cited by 56
Thavasu, P., PROPPER, D. J., McDonald, A. C., Dobbs, N. A., Ganesan, T. S., Talbot, D., Braybrook, J., Caponigro, F., Hutchison, C., Twelves, C., et al. (1999) · PubMed · Cited by 51
Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells
Courage, C., Snowden, R. T., & Gescher, A. J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.517 · Cited by 31
Bauer, K. S., Lush, R. M., Rudek, M. A., Shih, C., Sausville, E. A., & Figg, W. D. (2000) · Biomedical Chromatography · Cited by 15
Self-citation
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Role of cell cycle in mediating sensitivity to radiotherapy
Pawlik, T. M., & Keyomarsi, K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.03.005 · Cited by 1,102
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Imidazoles as potential anticancer agents
Ali, I., Lone, M. N., & Aboul-Enein, H. Y. (2017) · Med. Chem. Commun. · doi:10.1039/c7md00067g · Cited by 409
Metadata
- Authors
- Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., Jing, X.-X., Roberge, M., Fuse, E., Kuwabara, T., & Senderowicz, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-04-15
- Volume
- 19
- Issue
- 8
- Pages
- 2319-2333
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1896635905
- Cited by
- 291
- References
- 33
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.